NSEGeneral Updates8 Oct 2026 · 8 Oct 2026, 03:57 pm

General Updates

Dr. Reddy's Laboratories Limited · DRREDDY

✦ AI SummaryRegulatory

Dr. Reddy's Laboratories Limited has informed the Exchange about a completed Pre-Approval Inspection (PAI) at its FTO-11 manufacturing facility in Pydibhimavaram, Andhra Pradesh by the United States Food and Drug Administration (USFDA), with two observations issued in a Form 483.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk6/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Dr. Reddy's Laboratories Limited has informed the Exchange about General Updates

Attachments (1)

📄

DRREDDY_08102026155720_SE_intimation_08102026_signed.pdf

pdf

Download →
View document text
Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.com October 8, 2026 National Stock Exchange of India Ltd. (Scrip Code: DRREDDY) BSE Limited (Scrip Code: 500124) New York Stock Exchange Inc. (Stock Code: RDY) NSE IFSC Ltd. (Stock Code: DRREDDY) Dear Sir/Madam, Ref: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 This is to inform you that the United States Food and Drug Administration (USFDA) completed a Pre- Approval Inspection (PAI) at our FTO-11 manufacturing facility in Pydibhimavaram, Andhra Pradesh. The inspection was conducted from October 5, 2026 to October 7, 2026. We have been issued a Form 483 with two observations, which we will address within the stipulated timeline. This is for your information and records. Thanking you, Yours faithfully, For Dr. Reddy’s Laboratories Limited K Randhir Singh Company Secretary, Compliance Officer & Head-CSR